QleanAir and BioLamina signs groundbreaking cleanroom contract

2021-08-26 08:30:00

QleanAir Holding AB (publ), the premium provider of solutions for clean indoor air, have signed a contract for a new cleanroom with BioLamina, a Swedish biotechnological company. The order is the company’s largest to date with a total value of 12,4 MSEK.

Stockholm-based biotechnology company, BioLamina develops products for cell culture based on genetically engineered proteins, so-called laminins (Biolaminin(R). BioLamina has selected QleanAir to develop and build a 340 m² large GMP-classed cleanroom for production and research within process development, matrix biology and cellular assays.

- We have chosen QleanAir because they could both project manage and deliver a solution tailored to our needs at high demands within a short time frame, says Anders Lindblad, Interim CEO of BioLamina. With this new facility, we will be able to four-fold our overall manufacturing capacity and better serve our customers within the fields of research and cell therapy. Production is scheduled to start in January 2022.

The order is QleanAir largest to date, both within the product category Room solutions and in total, since the company was founded. The order is a product sale of 12.4 MSEK that will be included in the order intake in the third quarter. In addition to the clean room order, there will be a separate service agreement. QleanAir’s cleanroom team will start working with situation analysis and solution design immediately, in close collaboration with representatives from BioLamina.

- We are very pleased to be a part of the very important scientific work being done by BioLamina. This order is a very strong validation of our offering within cleanrooms and our track record of delivering clean room solutions to leading organizations within life science and biotechnology, says Christina Lindstedt, CEO of QleanAir.

BioLamina AB is a Swedish biotechnology company built on a scientific foundation with a legacy in matrix biology and cell culture-based research. Their flagship products, their biorelevant human recombinant laminin isoforms, Biolaminin®, are defined cell culture matrices that successfully imitate the natural, cell-specific cell-matrix interaction in the cell culture dish, allowing the cells to thrive and maintain their function. Their products are a powerful resource for scientists working with stem cells and primary cells both within basic research as well as in regenerative medicine companies with focus on cell therapy applications.

MFN